Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Risk adjusted net present value: What is the current valuation of Novo Nordisk's HS-001?
HS-001 is a cell therapy commercialized by Novo Nordisk, with a leading Phase II program in Systolic Heart Failure. According...